A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
10/2001
10/25/2001	WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001	WO2001079162A2 INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES
10/25/2001	WO2001079157A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078768A2 Targeted vaccine delivery systems
10/25/2001	WO2001078763A1 Use of npy y1 receptor antagonists in the treatment of inflammatory conditions
10/25/2001	WO2001078762A1 Use of npy y1 receptor agonists in the treatment of pain conditions
10/25/2001	WO2001078760A2 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001	WO2001078734A1 Methods of treatment
10/25/2001	WO2001078723A1 Compounds and methods
10/25/2001	WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078703A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001	WO2001078702A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001	WO2001078698A2 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
10/25/2001	WO2001078690A1 Patch containing anti-inflammatory agent
10/25/2001	WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	WO2001078580A2 A method combining inducing hypothermia and administering a therapeutic agent
10/25/2001	WO2001078533A2 Nutritional modules
10/25/2001	WO2001049288A9 Novel compounds and compositions as protease inhibitors
10/25/2001	WO2001039786A3 New uses of suppressive macrophage activation factors
10/25/2001	WO2001028987A8 Benzylcycloalkyl amines as modulators of chemokine receptor activity
10/25/2001	WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001	WO2001023570A3 Methods and compositions relating to sodium channel beta-1a subunits
10/25/2001	WO2001012790A3 Isomerase proteins
10/25/2001	WO2000061541A8 Pharmaceutical compounds
10/25/2001	WO2000054761A9 Regulation of phospholipase d activity
10/25/2001	WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001	US20010034353 Administering a mixture of antibiotic, nonsteroid antiinflammatory drug and a quinolone compound
10/25/2001	US20010034348 Nitric oxide synthase inhibitor; nervous system disorders
10/25/2001	US20010034340 Hormone replacement therapy
10/25/2001	US20010034331 Isolated polypeptide
10/25/2001	US20010034328 Treatment of male chronic pelvic pain syndrome
10/25/2001	US20010033836 Transgenic autologous T-cell therapy in humans, and related compositions and kits
10/25/2001	DE10020517A1 New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
10/25/2001	CA2747325A1 Albumin fusion proteins
10/25/2001	CA2485920A1 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001	CA2485919A1 Method for treating pain by peripheral administration of a neurotoxin
10/25/2001	CA2407531A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001	CA2406442A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001	CA2406378A1 Targeted vaccine delivery systems
10/25/2001	CA2406247A1 Inhibitors of the ice/ced-3 family of cysteine proteases
10/25/2001	CA2406245A1 Il-174 uses, compositions and methods
10/25/2001	CA2406190A1 Screening method for compounds
10/25/2001	CA2405709A1 Albumin fusion proteins
10/25/2001	CA2405701A1 Albumin fusion proteins
10/25/2001	CA2405600A1 Use of npy y1 receptor antagonists in the treatment of inflammatory conditions
10/25/2001	CA2405597A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001	CA2405563A1 Albumin fusion proteins
10/25/2001	CA2405557A1 Albumin fusion proteins
10/25/2001	CA2405550A1 Albumin fusion proteins
10/25/2001	CA2405525A1 Albumin fusion proteins
10/25/2001	CA2405451A1 Molecules associated with human reproduction
10/25/2001	CA2405377A1 Nutritional modules
10/25/2001	CA2404117A1 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
10/25/2001	CA2403644A1 Drug metabolizing enzymes
10/25/2001	CA2403508A1 Extracellular matrix polynucleotides, polypeptides, and antibodies
10/25/2001	CA2403490A1 N-substituted dithiocarbamates for the treatment of biological disorders
10/24/2001	EP1148059A1 Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof
10/24/2001	EP1147785A2 Therapeutic light source
10/24/2001	EP1147776A2 Use of botulinum toxin type B for the manufacture of a medicament for the treatment of muscle spasms
10/24/2001	EP1147775A2 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder
10/24/2001	EP1147119A1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors
10/24/2001	EP1147107A1 Novel angiogenesis inhibitors
10/24/2001	EP1147104A1 Aromatic heterocyclic compounds as antiinflammatory agents
10/24/2001	EP1147102A2 Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1147101A1 Reverse hydroxamate inhibitors of matrix metalloproteinases
10/24/2001	EP1147097A1 Peptidyl heterocyclic ketones useful as tryptase inhibitors
10/24/2001	EP1147095A1 2, 3, 4, 5-tetrahydro-1h-[1, 4] benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
10/24/2001	EP1147092A1 Substituted imidazoles, their preparation and use
10/24/2001	EP1147091A2 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
10/24/2001	EP1147089A1 Phenylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147088A1 6-arylphenanthridines with pde-iv inhibiting activity
10/24/2001	EP1147080A1 Alkynyl containing hydroxamic acid compounds as tace inhibitors
10/24/2001	EP1147079A2 Beta-phenylalanine derivatives as integrin antagonists
10/24/2001	EP1147078A1 Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
10/24/2001	EP1146913A2 Conjugates of colony stimulating factors for targeting and imaging infection and inflammation
10/24/2001	EP1146908A1 Formulations comprising antisense nucleotides to connexins
10/24/2001	EP1146907A2 Use of cationic lipids to generate anti-tumor immunity
10/24/2001	EP1146905A1 Cox-2 inhibitors in combination with nmda-blockers for treating pain
10/24/2001	EP1146902A1 Treatment of autommune diseases by an agonistic cd40-binding protein
10/24/2001	EP1146894A1 Uses of thank, a tnf homologue that activates apoptosis
10/24/2001	EP1146892A2 Baff, inhibitors thereof and their use in the modulation of the b-cell response
10/24/2001	EP1146889A2 Identification of specific differentially expressed mycobacterial antigens
10/24/2001	EP1146888A2 Specific therapeutic interventions obtained by interference with redistribution and/or targetting
10/24/2001	EP1146883A1 Modulation of immune response by ribavirin
10/24/2001	EP1146875A1 Myt1 kinase inhibitors
10/24/2001	EP1146874A1 Vitronectin receptor antagonist
10/24/2001	EP1146870A1 Antioxidant compositions and methods for companion animals
10/24/2001	EP1146868A1 Anti-inflammatory agents
10/24/2001	EP1146862A1 Pharmaceutical compositions
10/24/2001	EP1146790A1 Compounds and methods
10/24/2001	EP1035824A4 A process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
10/24/2001	EP0869955B1 N-acyl-2-substituted-4-(benzimidazolyl- or imidazopyridinyl-substituted residues)-piperidines as tachykinin antagonists
10/24/2001	EP0731709B1 Neutrophil inhibitors from nematodes
10/24/2001	CN1319139A Polynucleotide constructs and uses thereof
10/24/2001	CN1319133A Short peptides which selectively modulate activity of protein kinases
10/24/2001	CN1319131A Method and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
10/24/2001	CN1319097A Benzoxazine and benzothiazine derivatives and their use in medicines
10/24/2001	CN1319096A Quinazoline derivatives and pharmaceutical applications thereof
10/24/2001	CN1319095A Imidazole compounds and their use as adenosine deaminase inhibitors

1 ... 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 ... 1272